Pfizer to Cut Medicaid Drug Prices

(WDNews) – Pfizer and  President Donald Trump have struck a deal that reportedly would lower Medicaid drug prices to match what the company charges in other developed nations, in exchange for tariff relief, according to officials familiar with the agreement.

Under the arrangement, Pfizer allegedly will offer “most-favored-nation” pricing on all new drugs in the U.S. and reduce costs for existing Medicaid drugs by as much as 85%, with average cuts around 50%, according to reports. The deal is said to include a three-year grace period during which Pfizer’s products would be exempt from targeted pharmaceutical tariffs, provided the company shifts more operations to U.S. manufacturing.

Trump, speaking from the Oval Office alongside Pfizer CEO Albert Bourla and Health Secretary Robert F. Kennedy Jr., said the U.S. would no longer subsidize medicine costs for other countries. He also announced a new “TrumpRx” direct-to-consumer website, set to launch in 2026, through which Americans could buy prescription drugs.

Analysts and industry insiders reportedly see the deal as favorable to the pharmaceutical industry, noting that Medicaid already receives significant discounts and rebates. Some say the Pfizer concessions may have only an incremental impact given existing state rebate systems.

Critics argue the arrangement may be too narrow. The pricing cuts will apply only to Medicaid, not Medicare, which spends far more on drugs. More than 70 million Americans are enrolled in Medicaid, yet drug spending in that program is significantly less than Medicare’s share.

Sen. Elizabeth Warren, D-Mass., said the deal was “a step in the right direction,” but allegedly falls short of what is necessary, urging Congress to pass broader legislation requiring rebates when drug prices rise faster than inflation.

State Medicaid officials and industry groups, according to reports, welcomed the price cuts but questioned whether they will be sustainable without similar commitments from other drugmakers and deeper structural reforms.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source